Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia
- 14 January 2005
- journal article
- clinical trial
- Published by Elsevier BV in American Heart Journal
- Vol. 149 (1), e1-e8
- https://doi.org/10.1016/j.ahj.2004.07.025
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patientsThe American Journal of Cardiology, 2003
- New National Cholesterol Education Program III Guidelines for Primary Prevention Lipid-Lowering Drug TherapyCirculation, 2002
- Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countriesThe Lancet, 2001
- Treating dyslipidaemia in primary careBMJ, 2000
- The Lipid Treatment Assessment Project (L-TAP)Archives of Internal Medicine, 2000
- Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatinJournal of the American College of Cardiology, 1998
- A Multicenter, Placebo-Controlled, Dose-Ranging Study of AtorvastatinJournal of Cardiovascular Pharmacology and Therapeutics, 1998
- The Cost of Reaching National Cholesterol Education Program (NCEP) Goals in Hypercholesterolaemic PatientsPharmacoEconomics, 1998
- EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal resultsEuropean Heart Journal, 1997
- Inadequate treatment with HMG-CoA reductase inhibitors by health care providersAmerican Journal Of Medicine, 1996